IgE to Ana o 3 Can Identify Cashew Allergy in Children

This article originally appeared here.
Share this content:
IgE to Ana o 3 Can Identify Cashew Allergy in Children
IgE to Ana o 3 Can Identify Cashew Allergy in Children

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- Specific immunoglobulin E (IgE) to the 2 S albumin from cashew, Ana o 3, can discriminate between cashew nut allergic and tolerant children, according to a study published online Sept. 19 in Allergy.

Lars Lange, M.D., from St. Marien-Hospital in Bonn, Germany, and colleagues conducted a multicenter study to analyze specific IgE to cashew extract and Ana o 3 as well as total IgE in children with suspected cashew allergy. Data were included for 61 patients: 42 allergic and 19 tolerant to cashew.

The researchers found that Ana o 3 discriminated between allergic and tolerant children in receiver operating curves better than cashew-specific IgE, with an area under the curve of 0.94 compared with 0.78. The diagnostic was not improved further with the ratio of Ana o 3-specific IgE to total IgE. In probability curves for Ana o 3-specific IgE, a 95 percent probability was estimated at 2.0 kU/l.

"Specific IgE to Ana o 3 is a valuable tool for the diagnosis of cashew allergy," the authors write. "Considering its positive predictive value it might allow to make a considerable number of oral challenges superfluous."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths